3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
2
Breast
2
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
36
Capecitabine
28
Trastuzumab
23
Paclitaxel
22
Surveys and Questionnaires
20
Cyclophosphamide
20
Gemcitabine
18
Docetaxel
18
Carboplatin
15
Nivolumab
14
Methods
14
Magnetic Resonance Spectroscopy
13
Early Intervention, Educational
13
Bevacizumab
13
Interviews as Topic
12
Blood Specimen Collection
12
fludarabine
11
Standard of Care
11
Irinotecan
11
olaparib
10
durvalumab
10
Specimen Handling
10
Psychiatric Rehabilitation
10
palbociclib
9
aldesleukin
9
Taxes
9
Fulvestrant
9
Fluorouracil
9
Exercise
9
Drug Therapy
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
AZD5305
×
Gastrointestinal
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled